海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
55件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Efficacy, Safety, and Pharmacokinetic Profile of ANB020 in Adults with Moderate to Severe Atopic Dermatitis
- Moderate-to-Severe Atopic Dermatitis MedDRA version: 20.0 Level: PT Classification code 10012438 Term: Dermatitis atopic System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Poland, United Kingdom, United States
- 2018-07-25
Authorised
- A Safety and Efficacy Study for Alzheimer's Disease (Prodromal AD)
- prodromal Alzheimer's Disease MedDRA version: 16.0 Level: HLT Classification code 10001897 Term: Alzheimer's disease (incl subtypes) System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Finland, France, Germany, Italy, Japan, Netherlands, New Zealand, Norway, South Africa, Spain, Switzerland, United Kingdom, United States
- 2013-09-17
Authorised
- A Clinical Trial to Evaluate the Effectivenes, Safety, and Tolerability of Patiromer for Oral Administration in Children and Adolescents aged 2 to < 18 Years with Chronic Kidney Disease and High Levels of Serum Potassium Concentration
- Chronic Kidney Disease and Hyperkalemia MedDRA version: 20.1 Level: LLT Classification code 10020647 Term: Hyperkalemia System Organ Class: 100000004861 ;Therapeutic area: Not possible to specify
- Bulgaria, Canada, Georgia, Germany, Poland, South Africa, Ukraine, United States
- 2016-12-16
Authorised
- A study to assess the long-term safety and efficacy of dupilumab administered in patients 6 to atopic dermatitis (eczema)
- Atopic dermatitis MedDRA version: 18.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Hungary, Poland, United Kingdom
- 2015-06-25
Authorised
- A study to determine the safety and tolerability of REGN668 in patients aged =6 to atopic dermatitis (eczema)
- Atopic dermatits MedDRA version: 18.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Hungary, Poland, United Kingdom
- 2014-12-29
Authorised
- A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy.
- Heterozygous Familial Hypercholesterolemia;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Canada, Czech Republic, France, Germany, Netherlands, Norway, Russian Federation, Spain, United Kingdom, United States
- 2011-11-18
Authorised
- This is a long term extention study in patients with Atopic Dermatitis, also named eczema, that helps to understand how Baricitinib works BREEZE-AD1
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Czech Republic, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Slovenia, Spain, Switzerland, Taiwan
- 2017-09-22
Authorised
- Clinical study in subjects with pancreatic adenocarcinoma to assess safety and efficacy of investigational product (eryaspase) when added to standard chemotherapy
- Pancreatic Adenocarcinoma MedDRA version: 20.0 Level: LLT Classification code 10051971 Term: Pancreatic adenocarcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
- 2018-06-20
Authorised
- Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying its Onset
- Mild cognitive impairment due to Alzheimer’s disease MedDRA version: 18.1 Level: LLT Classification code 10009846 Term: Cognitive impairment System Organ Class: 100000004852 ;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Australia, Germany, Italy, Switzerland, United Kingdom, United States
- 2013-05-01
Authorised
- An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.
- FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer MedDRA version: 18.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
- 2013-06-12